Items

Maligni tumori gastrointestinalnog trakta, algoritmi i protokoli za kliničku praksu (2014)

S. Jungić, B. Tubić, Z. Gojković, I. Rakita, S. Mijatović, G. Marić, M. Vještica, M. Vižin, J. Rožić, P. Dašić, Maligni tumori gastrointestinalnog trakta, algoritmi i protokoli za kliničku praksu, Stručna knjiga izdata od domaćeg izdavača, Udruženje onkologa Republike Srpske, Banja Luka, 2014
Enhanced Dissolution of Anticancer Drug Letrozole from Mesoporous Zeolite Clinoptilolite (2023-09)

R. Kukobat, R. Škrbić, F. Vallejos-Burgos, E. Mercadelli, D. Gardini, L. Silvestroni, C. Zanelli, L. Esposito, D. Stević, S. Gotovac-Atlagić, D. Bodroža, Ž. Gagić, S. Pilipović, B. Tubić, N. Bubić Pajić, Enhanced Dissolution of Anticancer Drug Letrozole from Mesoporous Zeolite Clinoptilolite, JOURNAL OF COLLOID AND INTERFACE SCIENCE, Vol. 653, pp. 170 - 178, Sep, 2023
ATC klasifikacija lijekova i praćenje njihove upotrebe metodologijom sa DDD jedinicama za lijekove registrovane u Republici Srpskoj (2007)

R. Škrbić, V. Marković Peković, S. Stoisavljević-Šatara, N. Grubiša, B. Tubić, ATC klasifikacija lijekova i praćenje njihove upotrebe metodologijom sa DDD jedinicama za lijekove registrovane u Republici Srpskoj, Agencija za lijekove Republike Srpske u saradnji sa Zavodom za farmakologiju, toksikologiju i kliničku farmakologiju Medicinski fakultet Banja Luka, 2007
Registar lijekova Republike Srpske sa osnovama farmakoterapije 2007 (2007)

S. Stoisavljević-Šatara, S. Dobrić, S. Milovanović, V. Marković-Peković, LJ. Kerić, S. Jungić, B. Tubić, Registar lijekova Republike Srpske sa osnovama farmakoterapije 2007, Agencija za lijekove Republike Srpske, Banja Luka, 2007
Registar lijekova Republike Srpske sa osnovama farmakoterapije (2008)

S. Stoisavljević-Šatara, S. Dobrić, S. Milovanović, V. Marković Peković, L. Kerić, S. Jungić, B. Tubić, Registar lijekova Republike Srpske sa osnovama farmakoterapije, Agencija za lijekove Republike Srpske, 2008
II Registar lijekova Bosne i Hercegovine 2011 (2011)

S. Jungić, B. Tubić, II Registar lijekova Bosne i Hercegovine 2011, Agencija za lijekove i medicinska sredstva BiH, 2011
The role of biomarkers in the development of novel cancer therapies (2012)

S. Jungić, B. Tubić, T. Skrepnik, The role of biomarkers in the development of novel cancer therapies, Drug Metabolism and Personalized Therapy, Vol. 27(2), pp. 89 - 99, 2012
Prospective Risk Assessment of Medicine Shortages in Europe and Israel: Findings and Implications. (2020-03)

N. Miljković, B. Godman, M. Kovačević, P. Polidori, L. Tzimis, T. Hoppe-Tichy, M. Saar, I. Antofie, L. Horvath, T. De Rijdt, R. Vida, E. Kkolou, D. Preece, B. Tubić, J. Peppard, A. Martinez, C. Garcia Yubero, R. Haddad, D. Rajinac, P. Zelić, H. Jenzer, F. Tartar, G. Gitler, M. Jeske, M. Davidescu, G. Beraud, D. Kuruc Poje, K. Sakstrup Haag, H. Fischer, I. Sviestina, G. Ljubojević, A. Markestad, V. Vujić-Aleksić, L. Nežić, A. Crkvenčić, J. Linnolahti, B. Ašanin, N. Duborija-Kovačević, T. Bochenek, I. Huys, B. Miljković, Prospective Risk Assessment of Medicine Shortages in Europe and Israel: Findings and Implications., Frontiers in Pharmacology, Vol. 11, No. 357, Mar, 2020
Computational study of pomegranate peel extract polyphenols as potential inhibitors of SARS-CoV-2 virus internalization (2021-01)

Suručić R, Tubić B., Stojiljković M. P., Djuric D.M, Travar M., Grabež M., Šavikin K., Škrbić R., Computational study of pomegranate peel extract polyphenols as potential inhibitors of SARS-CoV-2 virus internalization, MOLECULAR AND CELLULAR BIOCHEMISTRY, Vol. 476, No. 2, pp. 1179 - 1193, Jan, 2021
Pomegranate peel extract polyphenols attenuate the SARS-CoV-2 S-glycoprotein binding ability to ACE2 receptor: In silico and in vitro studies (2021-07)

R. Suručić, M. Travar, M. Petković, B. Tubić, M. Stojiljković, M. Grabež, K. Šavikin, G. Zdunić, R. Škrbić, Pomegranate peel extract polyphenols attenuate the SARS-CoV-2 S-glycoprotein binding ability to ACE2 receptor: In silico and in vitro studies, BIOORGANIC CHEMISTRY, Vol. 114, pp. 105145 - 7, Jul, 2021
Biosimilars are essential for sustainable healthcare systems; however, key challenges remain as seen with long-acting insulin analogues (2022-03)

B. Godman, B. Tubić, E. Allocati, M. Wladysiuk, S. McTaggart, A. Kurdi, M. Haque, S. McBride-Stewart, F. Kalemeera, A. Massele, I. Hoxha, V. Marković Peković, G. Petrova, K. Tachkov, O. Laius, A. Harsanyi, A. Inotai, A. Jakupi, S. Henkuzens, K. Garuoliene, P. Vella Bonanno, J. Rutkowski, I. Mardare, J. Furst, C. Pontes, C. Zara, M. Turu Pedrola, F. Akter, H. Kwon, A. Martin, R. Banzi, J. Wale, J. Gulbinovic, Biosimilars are essential for sustainable healthcare systems; however, key challenges remain as seen with long-acting insulin analogues, Journal of Applied Pharmaceutical Science, Vol. 12, No. 3, pp. 055 - 072, Mar, 2022
First Experiences With the Use of Targeted and Immunotherapy in the Treatment of Cutaneous Melanoma: a Single Centre Experience (2022-03)

J. Berendika, S. Jungić, B. Tubić, I. Rakita, M. Vještica, D. Đokanović, Z. Gojković, N. Mirčeta, S. Petković, V. Marković Peković, First Experiences With the Use of Targeted and Immunotherapy in the Treatment of Cutaneous Melanoma: a Single Centre Experience, SCRIPTA MEDICA, Vol. 53, No. 1, pp. 29 - 35, Mar, 2022
Osvrt na farmakoterapijski asortiman citostatika u Republici Srpskoj (2010)

S. Jungić, N. Babić, T. Nedimović, B. Tubić, N. Grubiša, S. Vladimirov, Osvrt na farmakoterapijski asortiman citostatika u Republici Srpskoj, IV Hrvatski Kongres farmacije 2010, Zbornik radova pp. 81., 2010
Comparative study of the dissolution rate of nimesulide from solid pharmaceutical forms for oral administration registered in Bosnia and Herzegovina (2014)

B. Tubić, Ž. Gagić, N. Bubić Pajić, Comparative study of the dissolution rate of nimesulide from solid pharmaceutical forms for oral administration registered in Bosnia and Herzegovina, Abstract book, pp. 382 - 383, 2014
Bevacizumab in combination with irinotecan and capecitabine as first line treatment for MCRC efficacy and safety. (2014-06)

S. Jungić, G. Kecman Malčić, I. Rakita, D. Jovanović, R. Gajanin, Z. Marić, T. Biljana, Z. Gojković, Bevacizumab in combination with irinotecan and capecitabine as first line treatment for MCRC efficacy and safety., Annals of Oncology 2014; 25 (Supplement 2):, pp. 68 - 68, Jun, 2014

Items

Maligni tumori gastrointestinalnog trakta, algoritmi i protokoli za kliničku praksu (2014)

Enhanced Dissolution of Anticancer Drug Letrozole from Mesoporous Zeolite Clinoptilolite (2023-09)

ATC klasifikacija lijekova i praćenje njihove upotrebe metodologijom sa DDD jedinicama za lijekove registrovane u Republici Srpskoj (2007)

Registar lijekova Republike Srpske sa osnovama farmakoterapije 2007 (2007)

Registar lijekova Republike Srpske sa osnovama farmakoterapije (2008)

II Registar lijekova Bosne i Hercegovine 2011 (2011)

The role of biomarkers in the development of novel cancer therapies (2012)

Prospective Risk Assessment of Medicine Shortages in Europe and Israel: Findings and Implications. (2020-03)

Computational study of pomegranate peel extract polyphenols as potential inhibitors of SARS-CoV-2 virus internalization (2021-01)

Pomegranate peel extract polyphenols attenuate the SARS-CoV-2 S-glycoprotein binding ability to ACE2 receptor: In silico and in vitro studies (2021-07)

Biosimilars are essential for sustainable healthcare systems; however, key challenges remain as seen with long-acting insulin analogues (2022-03)

First Experiences With the Use of Targeted and Immunotherapy in the Treatment of Cutaneous Melanoma: a Single Centre Experience (2022-03)

Osvrt na farmakoterapijski asortiman citostatika u Republici Srpskoj (2010)

Comparative study of the dissolution rate of nimesulide from solid pharmaceutical forms for oral administration registered in Bosnia and Herzegovina (2014)

Bevacizumab in combination with irinotecan and capecitabine as first line treatment for MCRC efficacy and safety. (2014-06)